C. Harrison

发表

Drug repositioning: Genetic signatures uncover new uses

C. Harrison, 2011, Nature Reviews Drug Discovery.

Coronavirus puts drug repurposing on the fast track

Charlotte Harrison, C. Harrison, 2020, Nature Biotechnology.

Supreme Court sides with MedImmune

C. Harrison, 2007 .

Anticancer drugs: Reactivating p53 tumour suppressor function

C. Harrison, 2012, Nature Reviews Drug Discovery.

In this issue

Katie Kingwell, Timo Hannay, P. Kirkpatrick, 2016, Nature Reviews Drug Discovery.

ACE for all – a molecular perspective

K. Acharya, C. Harrison, 2014, Journal of Cell Communication and Signaling.

Immune regulation: IL-35: a new player in B cell activity

C. Harrison, 2014, Nature Reviews Drug Discovery.

Cancer: Intratumour heterogeneity

C. Harrison, 2012, Nature Reviews Drug Discovery.

In this issue

Sarah Crunkhorn, Timo Hannay, P. Kirkpatrick, 2008, Nature Reviews Drug Discovery.

Obesity and diabetes: CD44 immune receptor linked to diabetes

C. Harrison, 2012, Nature Reviews Drug Discovery.

Inflammatory disorders: Of mice and humans

C. Harrison, 2013, Nature Reviews Drug Discovery.

Ageing: Secrets of a long life

C. Harrison, 2009, Nature Reviews Drug Discovery.

Patenting natural products just got harder

C. Harrison, 2014, Nature Biotechnology.

Lung disease: Blocking TGFβ improves emphysema

C. Harrison, 2012, Nature Reviews Drug Discovery.

G-protein-coupled receptors: Crystal clear

C. Harrison, 2008, Nature Reviews Drug Discovery.

G protein-coupled receptors: Crystal structures aid ligand mechanistics

C. Harrison, 2013, Nature Reviews Drug Discovery.

G protein-coupled receptors: Insights into chemokine receptors

C. Harrison, 2010, Nature Reviews Drug Discovery.

Trial watch: BTK inhibitor shows positive results in B cell malignancies

C. Harrison, 2012, Nature Reviews Drug Discovery.

Cardiovascular disorders: MicroRNA modulation of cholesterol

C. Harrison, 2010, Nature Reviews Drug Discovery.

Pharmacokinetics: Single-cell imaging adds insight into drug action

C. Harrison, 2013, Nature Reviews Drug Discovery.

Computational biology: Structural insights into allosteric GPCR drugs

C. Harrison, 2013, Nature Reviews Drug Discovery.

Obesity and diabetes: A new player in type 2 diabetes

C. Harrison, 2010, Nature Reviews Drug Discovery.

Analgesia: Inhibiting neuropathic pain

C. Harrison, 2011, Nature Reviews Drug Discovery.

Vaccines: Structure-based design

C. Harrison, 2011, Nature Reviews Drug Discovery.

Trial watch: Opioid receptor blocker shows promise in Phase II depression trial

C. Harrison, 2013, Nature Reviews Drug Discovery.

Memory: Fingolimod modulates bad memories

C. Harrison, 2014, Nature Reviews Drug Discovery.

Chemical biology: Branching out into chemical space

C. Harrison, 2009, Nature Reviews Drug Discovery.

Chemical genetics: Genome-wide target identification

C. Harrison, 2014, Nature Reviews Drug Discovery.

Anticancer drugs: Epigenetic reprogramming sensitizes leukaemia to drug treatment

C. Harrison, 2012, Nature Reviews Drug Discovery.

Antivirals: New clues for broad-spectrum flu combat

C. Harrison, 2009, Nature Reviews Drug Discovery.

Cancer: A new target in Burkitt's lymphoma

C. Harrison, 2012, Nature Reviews Drug Discovery.

Lead discovery: Small-molecule inhibitors of cytoplasmic dynein

C. Harrison, 2012, Nature Reviews Drug Discovery.

Obesity and diabetes: Mitochondrial uncoupler blocks metabolic disease

C. Harrison, 2013, Nature Reviews Drug Discovery.

Anticancer drugs: Hitting SYK in B-ALL leukaemia

C. Harrison, 2014, Nature Reviews Drug Discovery.

Patent Watch

C. Harrison, 2009, Nature Reviews Drug Discovery.

Mood disorders: Antidepressant action through gene regulation

C. Harrison, 2009, Nature Reviews Drug Discovery.

Affective disorders: Antidepressant action through gene regulation

C. Harrison, 2009, Nature Reviews Neuroscience.

Anticancer Drugs: Partnering to promote apoptosis

C. Harrison, 2008, Nature Reviews Drug Discovery.

Focus shifts to antibody cocktails for COVID-19 cytokine storm

C. Harrison, 2020, Nature Biotechnology.

Osteoporosis: Building up the bone

C. Harrison, 2007, Nature Reviews Drug Discovery.

Vaccines: Nanorings boost vaccine adjuvant effects

C. Harrison, 2014, Nature Reviews Drug Discovery.

Anticancer drugs: New approaches to anti-androgen activities

C. Harrison, 2009, Nature Reviews Drug Discovery.

Neurodevelopmental disorders: Glutamate blockers show benefit in models of autism spectrum disorders

C. Harrison, 2012, Nature reviews. Drug discovery.

MDMA-assisted therapy for severe PTSD: a randomized, double-blind, placebo-controlled phase 3 study

Jennifer M. Mitchell, Julie B. Wang, R. Amiaz, 2021, Nature Medicine.

Pilot study suggests DNA methylation of the glucocorticoid receptor gene (NR3C1) is associated with MDMA-assisted therapy treatment response for severe PTSD

R. Yehuda, C. Lewis, C. Harrison, 2023, Frontiers in Psychiatry.

Anticancer drugs: Reprogramming metabolism in lung cancer

C. Harrison, 2014, Nature Reviews Drug Discovery.

Structure based inhibitor design studies on angiotensin converting enzyme homologues

C. Harrison, 2015 .

ACE for all – a molecular perspective

K. Acharya, C. Harrison, 2014, Journal of Cell Communication and Signaling.

Crystal structures of angiotensin converting enzyme from Anopheles gambiae in its native form and with a bound inhibitor.

K. Acharya, R. Isaac, G. Cozier, 2019, The Biochemical journal.

Anticancer drugs: Mitotic arrest

C. Harrison, 2007, Nature Reviews Drug Discovery.

Anticancer drugs: A new target for melanoma

C. Harrison, 2013, Nature Reviews Drug Discovery.

Stem cells: Ethical sourcing?

C. Harrison, 2007, Nature Reviews Drug Discovery.

Cancer: A target for drug resistance

C. Harrison, 2013, Nature Reviews Drug Discovery.

Autoimmune disease: Targeting IL-7 reverses type 1 diabetes

C. Harrison, 2012, Nature Reviews Drug Discovery.

G protein-coupled receptors: A double attack on pain

C. Harrison, 2013, Nature Reviews Drug Discovery.

Inflammatory disorders: Steroids modulate microglia-mediated inflammation

C. Harrison, 2011, Nature Reviews Drug Discovery.

Fibrotic disease: A pair of novel targets

C. Harrison, 2009, Nature Reviews Drug Discovery.

Deal watch: Chiasma and Roche partner in oral peptide drug delivery

C. Harrison, 2013, Nature reviews. Drug discovery.

Cardiovascular disease: Reducing the pressure

C. Harrison, 2007, Nature Reviews Drug Discovery.

Lung disorders: A new model and modulator of pulmonary oedema

C. Harrison, 2012, Nature Reviews Drug Discovery.

Nanotechnology: Biological proteins knock nanoparticles off target

C. Harrison, 2013, Nature Reviews Drug Discovery.

Kinase inhibitors: Analysing kinase inhibitor selectivity

C. Harrison, 2012, Nature Reviews Drug Discovery.

Diabetes: A mechanism of metabolically driven pain

C. Harrison, 2012, Nature Reviews Drug Discovery.

Sepsis: Calming the cytokine storm

C. Harrison, 2010, Nature Reviews Drug Discovery.

Patent battle lines drawn as sofosbuvir gains approval

C. Harrison, 2013, Nature reviews. Drug discovery.

Bone disorders: Clopidogrel prevents bone loss

C. Harrison, 2012, Nature Reviews Drug Discovery.

Neurodegenerative disease: A new pathway to autophagy

C. Harrison, 2008, Nature Reviews Drug Discovery.

Patent watch

C. Harrison, 2002, Nature Reviews Drug Discovery.

Target identification: Targeting neuronal loss in Gaucher's disease

C. Harrison, 2014, Nature Reviews Drug Discovery.

Anticancer drugs: Blocking phospholipid–protein interactions

C. Harrison, 2010, Nature Reviews Drug Discovery.

Genetic diseases: New tricks for known drugs

C. Harrison, 2010, Nature Reviews Drug Discovery.

Target validation: Tinkering with heart disease

C. Harrison, 2013, Nature reviews. Drug discovery.

The patent cliff steepens

Charlotte Harrison, C. Harrison, 2010, Nature Reviews Drug Discovery.

Cardiovascular disease: Inhibiting microRNA-34 benefits heart disease

C. Harrison, 2012, Nature reviews. Drug discovery.

Target validation: Tinkering with heart disease

C. Harrison, 2013, Nature Reviews Drug Discovery.

Cancer: IL-22: linking inflammation and cancer

C. Harrison, 2013, Nature Reviews Drug Discovery.

Ocular disorders: A new target in age-related macular degeneration

C. Harrison, 2013, Nature Reviews Drug Discovery.

Genetic disorders: A way to prevent heat-induced sudden death?

C. Harrison, 2012, Nature Reviews Drug Discovery.

Persistent neuropathological effects 14 years following amyloid- b immunization in Alzheimer’s disease

C. Holmes, S. Love, A. Page, 2019 .

Stem cells: A model of cardiomyopathy

C. Harrison, 2012, Nature Reviews Drug Discovery.

First gene therapy for β-thalassemia approved

C. Harrison, 2019, Nature Biotechnology.

Seven-transmembrane receptors: One way only

Charlotte Harrison, C. Harrison, 2009, Nature Reviews Drug Discovery.

Analgesia: Erasing the traces of pain

C. Harrison, 2012, Nature Reviews Drug Discovery.

Translational genetics: Signatures for drug repositioning

C. Harrison, 2011, Nature Reviews Genetics.

Obesity and diabetes: Two-for-one strike at incretins

C. Harrison, 2014, Nature Reviews Drug Discovery.